Latest Clinical Data on Weight Loss Drugs Metsera - MET-097 Om September 24, 2024, Metsera announced that its long-acting weight loss therapy, MET-097, achieved significant and lasting weight loss effects in a phase 1 clinical trial
Made in Germany, vegan, free from fillers, non-GMO, sugar-free, lactose-free, gluten-free, gelatin-free, nanoparticle-free, excellent bioavailability due to gentle production technologies without heat generation and without additives such as magnesium stearate or flow agents like silica dioxide
It is still too early to assess the promise of these cell therapy assets relative to semaglutide and tirzepatide
This means that it quickly and efficiently lowers blood sugar levels while having a decreased risk of hypoglycemia, especially when compared to other treatments, such as self-administered insulin
Sam Hawley: Yeah, and in the beginning it was like a drug for Hollywood celebrities and influencers
What matters most is finding an approach that fits your body, your health needs, and your life